S Protein and COVID-19: a Monocentric Prospective Study (PROS-Covid)

University of Milano Bicocca

Status

Enrolling

Conditions

COVID-19

Treatments

Procedure: Real Time PCR

Procedure: Sflt1 assay COVID+

Procedure: Hematolgy and Chemistry analysis

Procedure: Sflt1 assay CONTROL

Procedure: PROS assay CONTROL

Procedure: PROS assay COVID+

Study type

Observational

Funder types

Other

Identifiers

PROS-Covid

Details and patient eligibility

About

The aim of this study is to compare plasma S Protein levels to SARS-CoV-2 viral load in COVID positive patients.

Full description

Non-pharmacological, non-interventional, prospective, monocentric study involving the use of biological materials.

There will be two cohorts:

The study involves analyzing biological samples collected for normal clinical practice.

In particular:

blood samples will be used for PROS and Sflt1 assay, haematological, biochemical and coagulation tests.
Samples deriving from nasopharyngeal swab or from Broncho-Alveolar Lavage (BAL) liquid will be used for Real time PCR analysis to evaluate the viral load of SARS CoV-2.

Enrollment

70 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Cohort COVID + :

Subjects aged ≥ 18 years.
Signing of the informed consent.
Positivity for SARS-CoV-2 by RealTimePCR from nasopharyngeal swab or bronchial wash.

Cohort Control:

Subjects aged ≥ 18 years.
Signing of the informed consent.
Diagnosis of pneumonia not related to SARS-CoV-2, demonstrated by negative swab.

Exclusion criteria

Patients with a diagnosis of congenital S Protein deficiency.
Patients who are taking oral anticoagulant therapy (TAO) or new oral anticoagulants (NAO).
Chronic liver failure (> 5 points on the Child-Pugh score).
Female subjects who are pregnant or on estrogen-progestogen replacement therapy.